| Dr Jennifer Hilliard Keah, MD | |
|
495 Thomas Jones Way, Suite 100, Exton, PA 19341-2553 | |
| (610) 524-4106 | |
| (610) 524-4168 |
| Full Name | Dr Jennifer Hilliard Keah |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 18 Years |
| Location | 495 Thomas Jones Way, Exton, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275713455 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD438264 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bayada Home Health Care, Inc. | Exton, PA | Home health agency |
| Penn Medicine Home Health | Bala cynwyd, PA | Home health agency |
| Chester County Hospital | West chester, PA | Hospital |
| Paoli Hospital | Paoli, PA | Hospital |
| Hospital Of Univ Of Pennsylvania | Philadelphia, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Clinical Care Associates Of The University Of Pennsylvania Health | 4688588866 | 517 |
News Archive
A new intermediate step and unexpected enzymatic activity in a metabolic pathway in the body, which could lead to new drug design for psychiatric and neurodegenerative diseases, has been discovered by researchers at Georgia State University.
Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).
Significant weaknesses undermine the global community's abilities to prevent, detect early, and respond efficiently to potentially deadly species-crossing microbes, such as the pandemic H1N1 influenza virus sweeping the globe, says a new report from the Institute of Medicine and National Research Council. The report provides a detailed plan for establishing and funding a comprehensive, globally coordinated system to identify novel zoonotic disease threats as early as possible wherever they arise so appropriate measures can be taken to prevent significant numbers of human illnesses and deaths, and livestock losses.
"For every 1,000 patient-years of PEPFAR-supported HIV treatment provided, 228 fewer HIV patients die, 449 fewer children become orphans, 61 fewer sexual HIV transmissions occur and 26 fewer 'vertical' transmissions (e.g. mother-to-child) occur," John Blanford of the CDC told the PEPFAR Scientific Advisory Board in Washington, D.C., on September 14, according to a post in the Center for Global Health Policy's "Science Speaks" blog.
A new study from Belgian researchers shows that antiviral drug Favipiravir could have a weak effect against the dreaded novel coronavirus or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as seen in hamster models. However, the study also finds there is no efficacy of the much-touted drug Hydroxychloroquine.
› Verified 5 days ago
| Entity Name | Clinical Care Associates Of The University Of Pennsylvania Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972682995 PECOS PAC ID: 4688588866 Enrollment ID: O20031113000301 |
News Archive
A new intermediate step and unexpected enzymatic activity in a metabolic pathway in the body, which could lead to new drug design for psychiatric and neurodegenerative diseases, has been discovered by researchers at Georgia State University.
Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).
Significant weaknesses undermine the global community's abilities to prevent, detect early, and respond efficiently to potentially deadly species-crossing microbes, such as the pandemic H1N1 influenza virus sweeping the globe, says a new report from the Institute of Medicine and National Research Council. The report provides a detailed plan for establishing and funding a comprehensive, globally coordinated system to identify novel zoonotic disease threats as early as possible wherever they arise so appropriate measures can be taken to prevent significant numbers of human illnesses and deaths, and livestock losses.
"For every 1,000 patient-years of PEPFAR-supported HIV treatment provided, 228 fewer HIV patients die, 449 fewer children become orphans, 61 fewer sexual HIV transmissions occur and 26 fewer 'vertical' transmissions (e.g. mother-to-child) occur," John Blanford of the CDC told the PEPFAR Scientific Advisory Board in Washington, D.C., on September 14, according to a post in the Center for Global Health Policy's "Science Speaks" blog.
A new study from Belgian researchers shows that antiviral drug Favipiravir could have a weak effect against the dreaded novel coronavirus or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as seen in hamster models. However, the study also finds there is no efficacy of the much-touted drug Hydroxychloroquine.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jennifer Hilliard Keah, MD 495 Thomas Jones Way, Suite 100, Exton, PA 19341-2553 Ph: (610) 524-4106 | Dr Jennifer Hilliard Keah, MD 495 Thomas Jones Way, Suite 100, Exton, PA 19341-2553 Ph: (610) 524-4106 |
News Archive
A new intermediate step and unexpected enzymatic activity in a metabolic pathway in the body, which could lead to new drug design for psychiatric and neurodegenerative diseases, has been discovered by researchers at Georgia State University.
Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).
Significant weaknesses undermine the global community's abilities to prevent, detect early, and respond efficiently to potentially deadly species-crossing microbes, such as the pandemic H1N1 influenza virus sweeping the globe, says a new report from the Institute of Medicine and National Research Council. The report provides a detailed plan for establishing and funding a comprehensive, globally coordinated system to identify novel zoonotic disease threats as early as possible wherever they arise so appropriate measures can be taken to prevent significant numbers of human illnesses and deaths, and livestock losses.
"For every 1,000 patient-years of PEPFAR-supported HIV treatment provided, 228 fewer HIV patients die, 449 fewer children become orphans, 61 fewer sexual HIV transmissions occur and 26 fewer 'vertical' transmissions (e.g. mother-to-child) occur," John Blanford of the CDC told the PEPFAR Scientific Advisory Board in Washington, D.C., on September 14, according to a post in the Center for Global Health Policy's "Science Speaks" blog.
A new study from Belgian researchers shows that antiviral drug Favipiravir could have a weak effect against the dreaded novel coronavirus or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as seen in hamster models. However, the study also finds there is no efficacy of the much-touted drug Hydroxychloroquine.
› Verified 5 days ago
Mrs. Corinne Ruggiero, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 605 Gordon Dr, Exton, PA 19341 Phone: 610-363-0248 Fax: 610-363-4004 | |
Jason E. Conwell, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 154 Exton Square Mall, Exton, PA 19341 Phone: 484-565-8500 Fax: 610-280-1595 | |
Michael Anthony Mcguire, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 770 W Lincoln Hwy, Exton, PA 19341 Phone: 610-269-1372 Fax: 610-269-6951 | |
Dr. Marina V. Makous, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 430 Exton Commons, Exton, PA 19341 Phone: 484-876-1362 Fax: 610-363-6131 | |
John N Khalifa, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 93 W Devon Dr, Suite 100, Exton, PA 19341 Phone: 610-321-0200 Fax: 610-594-2625 | |
Emilia Sophia Kleinman, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 154 Exton Square Mall, Exton, PA 19341 Phone: 484-565-8500 Fax: 610-280-1595 | |
Meghan Elizabeth Wesolowski, CRNP Family Medicine Medicare: Medicare Enrolled Practice Location: 860 Springdale Dr Ste 100, Exton, PA 19341 Phone: 610-524-3703 Fax: 610-524-5990 |